Aurobindo Pharma is currently reporting losses at its China-based manufacturing site but expects the facility to reach break-even between the third and fourth quarter of fiscal year 2026. The company’s CFO, S. Subramanian, indicated that while the plant is operating below margin, it is ramping up production and is on track to contribute positively to the company’s EBITDA in the near future.

The China facility, which makes oral solid dosage products, is scaling up rapidly and aims to hit a capacity of two billion units. This follows recent approvals for ten products in Europe and three for the local market, underscoring the plant’s strategic importance to Aurobindo’s global operations.

On the financial front, the company remains optimistic, projecting overall EBITDA margins of 20–21 percent in FY26. Growth drivers include the expansion of its penicillin facility, an increasing biosimilar portfolio, and a developing biologic CMO business. Aurobindo is relying on these areas to improve profitability as it scales across markets.